Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vistagen Therapeutics (VTGN) Shares Outstanding (Weighted Average) (2017 - 2025)

Historic Shares Outstanding (Weighted Average) for Vistagen Therapeutics (VTGN) over the last 11 years, with Q4 2025 value amounting to $42.2 million.

  • Vistagen Therapeutics' Shares Outstanding (Weighted Average) rose 3751.82% to $42.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $42.2 million, marking a year-over-year increase of 3751.82%. This contributed to the annual value of $30.9 million for FY2025, which is 5953.41% up from last year.
  • As of Q4 2025, Vistagen Therapeutics' Shares Outstanding (Weighted Average) stood at $42.2 million, which was up 3751.82% from $35.7 million recorded in Q3 2025.
  • In the past 5 years, Vistagen Therapeutics' Shares Outstanding (Weighted Average) ranged from a high of $86.1 million in Q1 2021 and a low of $6.3 million during Q2 2021
  • Moreover, its 5-year median value for Shares Outstanding (Weighted Average) was $14.7 million (2023), whereas its average is $22.0 million.
  • As far as peak fluctuations go, Vistagen Therapeutics' Shares Outstanding (Weighted Average) tumbled by 9200.73% in 2022, and later soared by 32624.77% in 2023.
  • Quarter analysis of 5 years shows Vistagen Therapeutics' Shares Outstanding (Weighted Average) stood at $6.7 million in 2021, then increased by 2.23% to $6.9 million in 2022, then surged by 326.25% to $29.4 million in 2023, then rose by 4.5% to $30.7 million in 2024, then surged by 37.52% to $42.2 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $42.2 million in Q4 2025, compared to $35.7 million in Q3 2025 and $31.9 million in Q2 2025.